711 STEWART AVE, SUITE 200, NEW YORK, NY
ProPhase Labs, Inc. Invites Investors to Webinar on February 3, 2026
ProPhase Labs Initiates Sale Process for BE-Smart™ Cancer Test
News, Underwriting Agreement
ProPhase Labs, Inc. Uplists Common Stock to OTCID Market
ProPhase Labs Enters $10 Million Stock Purchase Agreement with Investor
Director Resignation - Warren Hirsch Steps Down from ProPhase Labs Board
Staff Determination Nasdaq Symbol: PRPH
Amended Quarterly Report
Q1
FY 2025
Notice of Late Filing for Quarterly Report
Notice of Late Filing for Annual Report
Q3
Q2
Prospectus filed pursuant to Rule 424(b)(5)
S-1
Prospectus filed pursuant to Rule 424(b)(3)
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
PRER14A
Notification Filed by a National Security Exchange
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Amended Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
S-8 POS
Free Writing Prospectus
Post-Effective Amendment to Registration Statement